For Q2 2026 ended June 30, Palvella Therapeutics (Nasdaq: PVLA) reported a net loss of $21.9 million, or $1.52 per basic and diluted share, compared with $9.5 million, or $0.86 per share, a year earlier. Higher R&D and administrative spending widened the loss as Palvella advanced its rolling NDA and clinical pipeline, while cash, cash equivalents and short-term investments totaled $250.6 million.
Core financial results
Operating expenses more than doubled year over year. R&D spending increased primarily because of manufacturing work, development of QTORIN rapamycin for angiokeratomas, the rolling NDA submission, and higher personnel and consulting costs. G&A expenses also rose due to increased headcount and public-company professional services.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| R&D expense | $12.47 million | $5.12 million | Up approximately 144% |
| G&A expense | $8.93 million | $4.13 million | Up approximately 116% |
| Total operating expenses | $21.41 million | $9.25 million | Up approximately 131% |
| Operating loss | $21.41 million | $9.25 million | Loss widened approximately 131% |
| Net loss | $21.87 million | $9.47 million | Loss widened approximately 131% |
| Basic and diluted loss per share | $1.52 | $0.86 | Loss per share widened approximately 77% |
Weighted-average shares used to calculate the quarterly loss per share increased to 14.36 million from 11.05 million. Despite that larger share base, the per-share loss still increased because the net loss more than doubled.
Business and pipeline progress
The principal operating milestone was the submission of the first module of the rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations. Palvella also continued preparations for additional trials across the QTORIN platform.
| Program | Latest update | Next disclosed milestone |
|---|---|---|
| QTORIN rapamycin — microcystic lymphatic malformations | First rolling NDA module submitted after the pre-NDA meeting; additional Phase 3 SELVA findings included a statistically significant improvement in patients aged 6–11 | Complete NDA submission in H2 2026; planned U.S. launch in H1 2027 if approved |
| QTORIN rapamycin — cutaneous venous malformations | Phase 2 TOIVA data showed improvement among all patients who had bleeding at baseline at Week 12, with additional 24-week results supporting longer treatment | Start Phase 3 trial in Q4 2026 after the End-of-Phase 2 meeting |
| QTORIN rapamycin — angiokeratomas | First patients dosed in the Phase 2 LOTU trial | Topline results in H2 2027 |
| QTORIN pitavastatin — DSAP | U.S. patent claims covering topical HMG-CoA reductase inhibitors for porokeratosis provide protection into 2043 | Start Phase 2 trial in H2 2026 |
Palvella also plans to announce a fourth target indication for QTORIN rapamycin and a third QTORIN platform product candidate during the second half of 2026.
Profitability, liquidity and the balance sheet
Cash and cash equivalents were $187.8 million at quarter-end, supplemented by $62.8 million in short-term investments. Their combined balance of $250.6 million was up from $58.0 million in cash and cash equivalents at December 31, 2025, although the release did not attribute the increase to a specific transaction.
Total current assets stood at $253.0 million, compared with current liabilities of $11.9 million. Total liabilities were $36.6 million and stockholders’ equity was $216.9 million. The release did not provide quarterly operating cash flow, free cash flow or a quantified cash-runway estimate, so the cash balance alone does not show the company’s current burn rate.
Pipeline execution is raising costs ahead of potential approval
The increase in spending directly reflects Palvella’s transition from clinical development toward regulatory review and possible commercialization. R&D costs rose with manufacturing, clinical work and the NDA process, while G&A costs increased as the company added personnel and operated as a public company.
At the same time, Palvella has begun pre-launch activities and recruited commercial and medical affairs leadership for a planned standalone U.S. launch. Because QTORIN rapamycin and QTORIN pitavastatin remain investigational, these investments are occurring before any disclosed product revenue and while the launch remains conditional on FDA approval.
Recent insider transactions
The supplied insider data shows 33,657 shares purchased and 25,812 shares sold during the last six months, resulting in net purchases of 7,845 shares across 16 transactions. The latest reported records were all classified as direct transactions; repeated derivative exercises followed by sales should be distinguished from open-market purchases.
| Date | Insider and role | Transaction | Reported value |
|---|---|---|---|
| 2026-07-15 | Kathleen Goin, COO | Derivative exercise/conversion at $7.14–$9.08 per share | $34,883 |
| 2026-07-15 | Kathleen Goin, COO | Sale at $147.14–$150.25 per share | $642,191 |
| 2026-06-17 | Kathleen Goin, COO | Derivative exercise/conversion at $7.14–$9.08 per share | $34,883 |
| 2026-06-17 | Kathleen Goin, COO | Sale at $110.26–$112.23 per share | $476,373 |
| 2026-06-12 | Matthew E. Korenberg, CFO | Derivative exercise/conversion at $13.60 per share | $13,600 |
| 2026-05-20 | Kathleen Goin, COO | Derivative exercise/conversion at $7.14–$9.08 per share | $34,883 |
| 2026-05-20 | Kathleen Goin, COO | Sale at $110.35–$111.90 per share | $475,631 |
| 2026-04-15 | Kathleen Goin, COO | Derivative exercise/conversion at $7.14–$9.08 per share | $34,883 |
| 2026-04-15 | Kathleen Goin, COO | Sale at $125.96–$130.33 per share | $547,399 |
| 2026-03-30 | George M. Jenkins, director | Purchase at $112.30 per share | $49,974 |
Risks investors need to monitor
- Regulatory timing and approval: The rolling NDA is not yet complete, and the planned first-half 2027 launch remains conditional on FDA approval.
- Clinical execution: The cutaneous venous malformation Phase 3 trial and the DSAP Phase 2 trial have not yet started, while angiokeratoma topline results are not expected until the second half of 2027.
- Rising operating costs: Quarterly operating expenses increased approximately 131%, reflecting simultaneous regulatory, manufacturing, clinical and staffing investments.
- Cash-use visibility: Palvella reported substantial liquidity but did not disclose quarterly cash flow or a quantified runway, limiting visibility into how long the current balance can support its expanding programs.
- Pre-launch spending: Commercial preparations are underway before approval, making the timing of the NDA review important to how efficiently those resources are deployed.
Summary
Palvella’s Q2 2026 results were defined by progress toward an NDA for QTORIN rapamycin and a substantially higher expense base supporting regulatory, manufacturing and clinical activity. The $250.6 million liquidity balance provides financial capacity, but the widening loss and absence of cash-flow data make spending trends important to monitor. The next major checkpoints are completion of the NDA, FDA review progress, and the planned starts of the cutaneous venous malformation and DSAP trials.
Find out more